Clinical Trials Browser

Phase 3 × Breast Neoplasms × Fluorouracil × Clear all

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

Phase 3 Active not recruiting

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

Phase 3 Completed

762 enrolled 14 charts

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Phase 3 Completed

Breast Neoplasms

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Phase 3 Completed

1,060 enrolled 20 charts

Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Phase 3 Completed

1,925 enrolled 19 charts

Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Phase 3 Completed

2,722 enrolled 14 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Phase 3 Completed

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

Breast Neoplasms

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Phase 3 Completed

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Phase 3 Completed

Breast Neoplasms

NCT00301925 2018-08-08

TACT2

Phase 3 Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Phase 3 Completed

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT02001506 2017-08-29

Neo-shorter

Phase 3 Completed

Breast Neoplasms

NCT01222052 2017-06-26

NNBC3-Europe

Phase 3 Unknown

Breast Neoplasms

NCT00331097 2017-03-28

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

Phase 3 Completed

Breast Neoplasms

NCT00544232 2016-02-15

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Phase 3 Completed

Breast Neoplasms

NCT02450058 2015-05-21

MIG5

Phase 3 Completed

Breast Neoplasms

NCT00002870 2014-12-16

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00003577 2013-12-19

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00003893 2013-12-19

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00005581 2013-12-18

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00002579 2013-11-06

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002581 2013-11-06

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002755 2013-11-06

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00017095 2013-10-24

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Phase 3 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00963729 2013-08-12

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

Phase 3 Completed

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00002696 2013-08-02

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

Phase 3 Suspended

Breast Neoplasms

NCT01031030 2013-08-02

Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)

Phase 3 Unknown

Breast Neoplasms

NCT00054587 2013-07-19

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00311636 2013-06-26

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 3 Completed

Breast Neoplasms

NCT00055679 2013-06-18

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00047099 2013-05-30

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002784 2013-04-04

15-95

Phase 3 Completed

Breast Neoplasms

NCT00929591 2013-01-24

SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00038402 2012-07-20

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00336791 2012-02-14

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00152178 2011-07-07

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)

Phase 3 Completed

Breast Neoplasms

NCT00193011 2011-05-03

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00688740 2011-02-16

TAX316

Phase 3 Completed

1,491 enrolled 12 charts

Breast Neoplasms